|
|
|
26.03.26 - 13:33
|
Pluri Secures Additional Investment from Chairman Alejandro Weinstein at 30% Premium to Market in a Private Placement (GlobeNewswire EN)
|
|
|
HAIFA, Israel, March 26, 2026 (GLOBE NEWSWIRE) -- Pluri Inc. (“Pluri” or the “Company”) (Nasdaq, TASE: PLUR), a biotechnology company leveraging a proprietary cell-based platform across multiple commercial verticals, today announced that an entity beneficially owned by Alejandro Weinstein, Chairman of the Board and one of the Company's largest shareholders, has entered into a Securities Purchase Agreement with Pluri for an additional $2.5 million investment in the Company at a 30% premium to the market price on March 24, 2026....
|
|
|
|
|
|
|
22.01.26 - 15:18
|
Pluri Successfully Completes First Phase of Resbiomed Program for Placenta-Derived Collagen-Rich Biomaterials (GlobeNewswire EN)
|
|
|
HAIFA, Israel, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Pluri, Inc. (“Pluri”, the “Company”, “we” or “us”) (Nasdaq, TASE: PLUR), a biotechnology company leveraging its proprietary platform for cell-based solutions through a collaborative network of ventures, today announced the completion of the first phase of its program with Resbiomed Technologies OOD (“Resbiomed”), a European biotechnology company developing extracellular-matrix-based biomaterials and biologics for regenerative medicine. The program is being executed through Pluri's contract development and manufacturing division, PluriCDMO™....
|
|
|
22.12.25 - 13:06
|
Pluri and Remedy Cell Expand Collaboration; Successful Engineering Runs and Clinical-Grade Manufacturing Achieved (GlobeNewswire EN)
|
|
|
HAIFA, Israel, Dec. 22, 2025 (GLOBE NEWSWIRE) -- Pluri, Inc. (“Pluri”, the “Company”, “we” or “us”) (Nasdaq, TASE: PLUR), a leading biotechnology company leveraging its proprietary platform for cell-based solutions through a collaborative network of ventures, today announced expansion of its manufacturing agreement signed in 2024 with Remedy Cell Ltd. (“Remedy Cell”), an innovative biopharmaceutical company developing stem cell-derived, cell-free therapeutics for complex fibrotic conditions....
|
|
|
09.12.25 - 14:33
|
Pluri Appoints Alejandro Weinstein as Chairman of the Board to Lead Strategic Shift and Unlock Value, Backed by Additional Investment (GlobeNewswire EN)
|
|
|
HAIFA, Israel, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Pluri Inc. (“Pluri” or the “Company”) (Nasdaq, TASE: PLUR), a biotechnology company leveraging a proprietary cell-based platform across multiple commercial verticals, today announced that Mr. Alejandro Weinstein, one of the Company's largest shareholders, has been appointed Chairman of the Board of Directors. The appointment reflects the Board's view that Mr. Weinstein brings a decisive, business driven perspective that aligns with Pluri's objectives of strengthening market positioning and accelerating the recognition and realization of the significant value embedded in the Company's underlying assets....
|
|
|
11.11.25 - 14:03
|
Pluri Partners with Miss Universe Skincare Introducing Exosome-Enhanced Regenerative Skincare (GlobeNewswire EN)
|
|
|
HAIFA, Israel, Nov. 11, 2025 (GLOBE NEWSWIRE) -- Pluri Inc. (“Pluri”, the “Company”, “we”, “our” or “us”) (Nasdaq, TASE: PLUR), a leading biotechnology company leveraging its proprietary platform for cell-based solutions to create a collaborative network of ventures, today announces the launch of Cellav Health and Aesthetics Ltd. (“Cellav”), its wholly-owned health and aesthetics subsidiary, focused on developing science-driven and regenerative solutions powered by Pluri's proprietary 3D cell expansion platform. The launch follows Cellav's first secured commercial collaboration with Miss Universe Skincare (“Miss Universe Skincare”), a global skincare and beauty brand. The collaboration will focus on the co-development of a new line of advanced, cell-based skincare products....
|
|
|
08.10.25 - 15:03
|
Pluri Subsidiary Coffeesai and Instituto del Café de Chiapas Announce Strategic Collaboration to Advance Cell-Based Coffee Manufacturing in Mexico (GlobeNewswire EN)
|
|
|
HAIFA, Israel, Oct. 08, 2025 (GLOBE NEWSWIRE) -- Pluri Inc. (“Pluri”, the “Company”, “we” or “us”) (Nasdaq, TASE: PLUR), a leading biotechnology company leveraging its proprietary platform for cell-based solutions through a collaborative network of ventures, today announced that Coffeesai Ltd. (“Coffeesai”), its wholly owned subsidiary developing sustainable cell-based coffee products, has signed an agreement with the Instituto del Café de Chiapas (INCAFECH), a public body of the State of Chiapas, Mexico, to advance cell-based coffee manufacturing in Mexico....
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
